Core Viewpoint - Anteris Technologies has secured a $90 million strategic investment from Medtronic, which follows a $320 million underwritten offering of common stock, aimed at advancing the global pivotal PARADIGM trial and commercializing the DurAVR® Transcatheter Heart Valve [1][3]. Group 1: Investment and Collaboration - The investment from Medtronic is seen as a significant milestone for Anteris, validating its program in the capital markets and indicating potential future collaborations [3]. - Anteris and Medtronic share a vision of advancing the Transcatheter Aortic Valve Replacement (TAVR) market through improved clinical science and valve design, focusing on durability and long-term patient outcomes [2][3]. Group 2: PARADIGM Trial - The PARADIGM Trial is a randomized controlled trial designed to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVR options, with an enrollment target of approximately 1,000 patients [4][5]. - The trial will assess non-inferiority based on a primary composite endpoint that includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure [5]. - Recruitment for the PARADIGM Trial has already begun, with the first patients enrolled in the fourth quarter of 2025 [6]. Group 3: Product Overview - Anteris' lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy aortic valve [8]. - The DurAVR® THV is constructed from Anteris' patented ADAPT® tissue technology, which has been clinically used for over 10 years and is FDA-cleared, having been distributed to over 55,000 patients globally [8].

Core Viewpoint - Anteris Technologies Global Corp. announced positive 30-day clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in patients with severe aortic stenosis and small aortic annuli, highlighting its potential for commercialization and improved patient outcomes [1][4][7]. Group 1: Clinical Outcomes - The DurAVR® THV showed single-digit mean gradients and large effective orifice areas (EOAs), with no moderate or severe paravalvular leaks and no valve-related mortality, achieving 97% freedom from moderate or severe prosthesis-patient mismatch (PPM) [1][10]. - The pooled analysis included 100 patients from the ongoing EMBARK study and early feasibility studies, focusing on those with small aortic annuli treated with the DurAVR® THV [6][10]. - The technical success rate was 100% in the last 50 consecutive patient implants, indicating high rates of technical and device success [10]. Group 2: Expert Commentary - Prof. Dr. Ole De Backer emphasized the favorable hemodynamic outcomes and low PPM rates, which are critical for patients with small annuli, suggesting a unique balance of benefits from the DurAVR® THV [4][5]. - Chris Meduri, M.D., noted the clinical relevance of achieving 97% freedom from moderate or severe PPM, particularly in small annuli patients where the risk is heightened [5]. Group 3: Future Prospects - The results from the 30-day outcomes align with the 1-year results presented at TCT, reinforcing confidence in the DurAVR® THV as a promising technology as the company advances towards commercialization [7]. - The global PARADIGM Trial will further evaluate the safety and effectiveness of the DurAVR® THV compared to existing transcatheter aortic valve replacements (TAVRs) [8].